Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34615706)

  • 1. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
    Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
    Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
    Morris LGT
    Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.
    Pyke RM; Mellacheruvu D; Dea S; Abbott CW; McDaniel L; Bhave DP; Zhang SV; Levy E; Bartha G; West J; Snyder MP; Chen RO; Boyle SM
    Nat Commun; 2022 Apr; 13(1):1925. PubMed ID: 35414054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
    Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
    Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
    Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
    Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
    Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
    Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
    McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
    Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.
    Koene GJ; Arts-Hilkes YH; van Dijk AJ; van der Ven KJ; Slootweg PJ; de Weger RA; Tilanus MG
    Hum Immunol; 2004 Dec; 65(12):1455-62. PubMed ID: 15603873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
    Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy.
    Zhang X; Tang H; Luo H; Lu H; Pan C; Yu H; Zhang L; Guan Y; Yu L; Chu H; Chen J; Wang J
    Front Genet; 2022; 13():1066636. PubMed ID: 36531232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.
    Abdel-Fatah TM; Arora A; Moseley PM; Perry C; Rakha EA; Green AR; Chan SY; Ellis IO; Madhusudan S
    Oncotarget; 2015 Sep; 6(26):21964-78. PubMed ID: 26267318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer.
    Wang XC; Zhang JQ; Shen YQ; Miao FQ; Xie W
    J Exp Clin Cancer Res; 2006 Mar; 25(1):115-9. PubMed ID: 16761627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data.
    Yu Z; Li A; Wang M
    BMC Med Genomics; 2017 Mar; 10(1):15. PubMed ID: 28298214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.